NUZ-001 shows positive early results, headed toward HEALEY trial

NUZ-001 shows positive early results, headed toward HEALEY trial

NUZ-001, which was previously known as monepantel, slowed lung function declines by nearly 50% in people with amyotrophic lateral sclerosis (ALS), according to new analyses from a Phase 1 trial. This slowing of respiratory declines was strongly correlated with slower declines in overall function that were observed in previous analyses. Developer Neurizon Therapeutics is using the data to finalize its plans for NUZ-001 to enter the HEALEY ALS pla…